Lancet sub-magazine or discover COVID-19 special effects medicine! Arthritis drug anawhitetar significantly improves respiratory function in patients with COVID-19 and reduces cytokine storm levels!

June 1, 2020 /
BiovalleyBIOON/- The first study using the treatmentrheumatoid arthritisdrug Anakinra to treat COVID-19 patients found that high doses of Anakinra were safe and associated with improved respiratory function and lower cytokine storm levels in patients with 72% (21/29)The 21-day study, which runs from 17 to March 27, 2020, was published recently in The Lancet RheumatologyAll 29 patients received standard care (noninvasive ventilation (CPAP), hydroxychloroquine, lopinavir/litonavir) and medication (daily high-dose intravenous anaquina(anakinra) weighing 10 mg/kg)They compared 16 patients who received only standard treatmentHowever, this study is not a randomized controlled trial, but is the gold standard for determining the effectiveness of treatmentProfessor Lorenzo Dagna, director of theImmunology, Rheumatology, Allergy and Rare Diseases at Vita-Salute San Raffaele University and San Raffaele Hospital in Milan, Italy, said: "Before a vaccine is available, we urgently need to find a way to help patients with severe COVID-19 surviveA treatment that has met rigorous safety testing is ideal, and the drug has enough quantities to meet the current pandemicimage source: https://cn.bing.com
Dr Giulio Cavalli from the same unit said: "Our study is the first to show that the high-dose arthritis drug Anakinra may be able to prevent over-reactions of the immune system caused by COVID-19The results are interesting, and the drug is worth a controlled trial in a large randomized trial "
most PATIENTs with COVID-19 have only mild symptoms, but in patients with severe illness, the immune system overreacts, triggering an immune protein storm called cytokines Cytokines cause excessive inflammation, leading to acute respiratory distress syndrome (ARDS) and reducing oxygen levels in the blood Acute respiratory distress syndrome (ARDS) is the leading cause of death from coronary virus disease The estimated mortality rate of COVID-19 and ARDS patients admitted to the intensive care unit was 28 to 78 per cent Patients need to breathe until the inflammation subsides, but the number of patients who need ventilation may exceed the number of intensive care units using mechanical ventilators There is an urgent need to treat patients with external critical illness of THE ICU to improve their prognosis Anakinra drugs have been approved by the U.S Food and Drug Administration and the European Medicines Agency to
treat , static diseases and recurrent fevers in rheumatoid arthritis It works by blocking protophilis cytokine IL-1 An earlier opinion piece published in The Lancet Rheumatology explains why intravenous anincanra may be effective and safe in treating cytokine storm syndrome The authors of the study noted that Anakinra has a higher safety and short half-life compared to other cytokine blockers and is suitable for use in critically ill patients In this study, 21 (72%) of the 29 patients were treated with high doses of Anakinra over a 21-day period, with reduced serum C-reactive protein and improved respiratory function The survival rate was 90% (26 / 29) Five of the 29 patients (17%) required mechanical ventilation The authors compared these observations with those of 16 patients who received standard treatment prior to the start of the study (March 10-17) In most of the 16 patients, the C-reactive protein continued or increased repeatedly Half of the patients (8 cases, 50%) had improved respiratory function and 56% (9 out of 16) survived 1 patient received mechanical ventilation (6%) The authors report that large doses of Anakinra are generally safe Among the of adverse reactions , four patients (14%) in the high-dose Anakinra group had bacteremia (
bacteria in the blood ), compared with 2 patients (13%) in the standard treatment group There is no recurrence of inflammation after the cessation of Anakinra Patients receiving high doses of anabinra (Anakinra) died from pulmonary thrombosis, respiratory insufficiency, and multiple organ failure (1 per death) The causes of death in the control group were respiratory insufficiency (3 cases), multi-organ failure (3 cases), and pulmonary thrombosis (1 case) Photo Source: The Lancet authors warn that the study's retrospective features and the small number of patients in the group are unlikely to draw firm conclusions These findings need to be validated by a controlled trial that takes longer to examine long-term results A randomized controlled trial of an intravenous Anakinra for the treatment of COVID-19 is under way, but the assessed dose is lower and does not include ARDS patients " The patients we studied were in serious condition, with an average age of 62 years, poor health and a high risk of dying from COVID-19 In these patients, high-dose intravenous Anakinra inhibits inflammation throughout the body and is associated with a gradual improvement in respiratory function These patients were treated outside the ICU in the context of the COVID-19 pandemic and the shortage of ICU resources Although the current emphasis on viral control is high, inflammation control may also be critical to the treatment of COVID-19 This seems to allow us to delay or avoid intubation in most patients Based on the results we have, this approach can be based on the availability of resources (BiovalleyBioon.com) References: Giulio Cavalli et al, Interleukin-1 blockade with high-dose Anakinra in patients with COVID-19, thyrisyndrome, and hyperifrif: a retrospective cohort study, LanceT Rheumatology (2020) DOI: 10.1016/S2665-9913 (20) 30127-2
Small study of patients with severe COVID-19 with theter the arthritis drug an findakins clinicals